CSPC Pharmaceutical Group Limited (CSPCY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

CSPC Pharmaceutical Group Limited (CSPCY) is down 15.6% since the beginning of the year. At $4 per share, CSPCY is trading 37.6% below its 52-week high of $6. Investors who bought $1,000 worth of CSPCY shares 5 years ago would now be looking at an investment worth $695.

CSPC Pharmaceutical Group Limited (CSPCY) has returned -15.55% so far this year and -1.12% over the past 12 months.

Based on dividend-adjusted daily data since Apr 8, 2019, CSPCY's average daily return is +0.22%, while the average monthly return is +4.36%. At this rate, an investment would double in approximately 1.4 years.

Historically, 46% of months were positive and 54% were negative. The best month was Aug 2019 with a return of +360.0%, while the worst month was Jul 2019 at -69.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CSPCY closed higher 41% of trading days. The best single day was Aug 1, 2019 with a return of +291.4%, while the worst single day was Jul 22, 2019 at -69.0%.

CSPC Pharmaceutical Group Limited has an annualized alpha of 68.65%, beta of 0.30, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 01, 2019.

• This stock tended to rise when S&P 500 Index fell (downside capture of -32.24%), but participation in market rallies was also limited (-3.81%) - a profile typical of counter-cyclical assets.
• Beta of 0.30 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CSPCY ranks 40 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for CSPC Pharmaceutical Group Limited (CSPCY) and compare them to S&P 500 Index.

CSPC Pharmaceutical Group Limited provided a 3.38% dividend yield over the last twelve months, with an annual payout of $0.12 per share.

The table displays the monthly dividend distributions for CSPC Pharmaceutical Group Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CSPC Pharmaceutical Group Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CSPC Pharmaceutical Group Limited was 69.41%, occurring on Jul 22, 2019. Recovery took 1 trading session.

The current CSPC Pharmaceutical Group Limited drawdown is 35.26%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CSPC Pharmaceutical Group Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CSPC Pharmaceutical Group Limited is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.